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Dried blood spot versus venous blood
sampling for phenylalanine and tyrosine
Kimber van Vliet1, Wiggert G. van Ginkel1, Esther van Dam1, Pim de Blaauw2, Martijn Koehorst2, Hermi A. Kingma2,
Francjan J. van Spronsen1 and M. Rebecca Heiner-Fokkema2*
Abstract
Background: This study investigated the agreement between various dried blood spot (DBS) and venous blood
sample measurements of phenylalanine and tyrosine concentrations in Phenylketonuria (PKU) and Tyrosinemia type
1 (TT1) patients.
Study design: Phenylalanine and tyrosine concentrations were studied in 45 PKU/TT1 patients in plasma from
venous blood in lithium heparin (LH) and EDTA tubes; venous blood from LH and EDTA tubes on a DBS card;
venous blood directly on a DBS card; and capillary blood on a DBS card. Plasma was analyzed with an amino acid
analyzer and DBS were analyzed with liquid chromatography-mass spectrometry. Agreement between different
methods was assessed using Passing and Bablok fit and Bland Altman analyses.
Results: In general, phenylalanine concentrations in LH plasma were comparable to capillary DBS, whereas tyrosine
concentrations were slightly higher in LH plasma (constant bias of 6.4 μmol/L). However, in the low phenylalanine
range, most samples had higher phenylalanine concentrations in DBS compared to LH plasma. Remarkably,
phenylalanine and tyrosine in EDTA plasma were higher compared to all other samples (slopes ranging from 7 to
12%). No differences were observed when comparing capillary DBS to other DBS.
Conclusions: Overall agreement between plasma and DBS is good. However, bias is specimen- (LH vs EDTA), and
possibly concentration- (low phenylalanine) dependent. Because of the overall good agreement, we recommend
the use of a DBS-plasma correction factor for DBS measurement. Each laboratory should determine their own factor
dependent on filter card type, extraction and calibration protocols taking the LH plasma values as gold standard.
Keywords: Phenylalanine, Tyrosine, Dried blood spots, Lithium heparin plasma, EDTA plasma, Tandem mass
spectrometry
Background
To improve the outcome in patients with phenylketon-
uria (PKU, OMIM #261600), frequent monitoring of
blood phenylalanine (Phe) concentrations is necessary
[1, 2]. Measurement of tyrosine (Tyr) concentrations can
be important as well in PKU, as Tyr and Phe/Tyr ratios
are found to be related to executive cognitive
functioning [3]. In Tyrosinemia type 1 (TT1, OMIM
#276700), attention usually focuses on monitoring Tyr
concentrations [4]. Some recent theoretical and clinical
studies suggested however that Phe concentrations could
also be important. Low Phe concentrations have been
related to impaired growth, skin problems and neuro-
logical deficits [5–8].
Monitoring Phe and Tyr concentrations is nowadays
increasingly done using dried blood spots (DBS). The
validity of the DBS for monitoring Phe is of ongoing de-
bate [9–12]. A pilot study in the Netherlands for
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example showed high variability between laboratories in
DBS Phe concentrations. Moreover, differences between
lithium heparin (LH) anticoagulated plasma and DBS
Phe concentrations among the participating laboratories
varied considerably (Coene et al. personal communica-
tions). This could, in part, be caused by the different
analytical methods used. On the other hand, differences
between DBS and venous blood might especially be
dependent on the applied calibration method and corre-
sponding correction factors.
Independent of the specific cause, the large inter-
laboratory variability in Phe concentrations has import-
ant implications for the patients treated in the different
centers, and patient monitoring when using (inter)-
national target values. There are few reports on the pos-
sible differences between Tyr concentrations in DBS and
venous plasma samples so far [10, 12], although it is
likely that the same uncertainties as with the measure-
ment of Phe exist.
The objective of this study was to investigate the
agreement between Phe and Tyr concentrations as mea-
sured in different types of blood sampling in our labora-
tory. For this, we compared lithium heparin- and EDTA-
plasma with capillary DBS. Additionally, we investigated
the agreement between DBS spotted from capillary or
different venous blood samples.
Methods
Subjects
In total, 40 PKU patients (18 male) and 5 TT1 patients
(4 male) were included in this study (mean age ± SD: 18
years ±12.5; range 0–48 years). Five PKU and 3 TT1 pa-
tients were included multiple times at different time
points to enhance the sample size (especially samples
with low Phe and high Tyr concentrations). All PKU pa-
tients were treated with a Phe restricted diet and/or tet-
rahydrobiopterin. All TT1 patients were treated with 2-
(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
(NTBC), dietary restriction of Phe and Tyr, and Phe sup-
plementation in case of otherwise very low plasma Phe
concentrations (< 30 μmol/L) [13]. The need for formal
ethical review was waived by the local ethics committee,
since we made use of blood that was drawn regularly
during outpatient visits. The study design was in accord-
ance with the current revision of the Helsinki Declar-
ation. All PKU and TT1 caregivers or patients gave
written informed consent for this study. Children gave
assent if age and understanding was appropriate accord-
ing to ethics guidelines.
Study design
In total, 53 measuring points in the outpatient clinic
were studied. For this study, the following six ways of
blood sampling were compared:
1) Plasma from venous blood sampling in regular
lithium heparin (LH) tubes;
2) Plasma from venous blood sampling in K2-EDTA
(EDTA) tubes;
3) Venous blood sampling from a LH tube on a DBS
card;
4) Venous blood sampling from an EDTA tube on a
DBS card;
5) Venous blood directly on a DBS card;
6) Capillary blood (by finger puncture) on a DBS card.
Venous blood was taken by venipuncture with a
butterfly needle and collected in LH tubes (which is the
regular tube in the UMC Groningen for Phe and Tyr
analysis), EDTA tubes, and sterile syringes. Blood spots
were made using blood from the syringe, and by taking a
drop of LH- and EDTA-anti-coagulated blood, corre-
sponding to approximately 40 μl, from the tubes and ap-
plying this on blood spot cards. In addition, blood spots
were made by collecting one drop of capillary blood on
a filter card by finger puncture (as is done at home). All
blood samples from the patient were taken at the same
time at the outpatient clinic to ensure minimal differ-
ences between the samples due to diurnal variation in
concentrations [13–16]. Blood spot cards were obtained
from Sartorius (TFN Grade 179 g/m2, Sartorius Stedim,
Göttingen, Germany).
Laboratory analyses
All samples were analyzed in the Laboratory of Meta-
bolic Disease of the UMC Groningen. The laboratory is
ISO15189 accredited (M078). Blood applied on filter
cards was dried for at least 3 h at room temperature.
DBS cards were stored at room temperature for 0–6 days
prior to analyses. Analyzed data were corrected using a
DBS-plasma correction factor as is practice in our hos-
pital. The correction factor was determined by compar-
ing concentrations of Phe and Tyr in DBS and plasma,
prepared from blood samples spiked with Phe and Tyr
(0–100–250-500-750-1000-1400 μmol/l). Phe and Tyr
concentrations in DBS were measured with LC-MS/MS,
using a calibration curve in 0.1 N HCl. Phe and Tyr con-
centrations in plasma were analyzed with Biochrom. De-
tails of the methods are described in the Supplemental
Materials. We then estimated the DBS-plasma correc-
tion factor using a Passing and Bablok regression ana-
lysis. In this analysis, Phe or Tyr concentrations in
plasma were plotted on the x-axis, and DBS concentra-
tions were plotted on the y-axis. The slope of the regres-
sion analyses, corresponding to 2.4 in our methods, was
applied as DBS-plasma correction factor. We applied the
DBS-plasma correction factor by adjusting the amount
of calibration solution used in our LC-MS/MS method.
The correction factor was subsequently verified using
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plasma and DBS samples prepared from blood samples
of patients. A more detailed description of the determin-
ation of the correction factor is presented in the Supple-
mental Materials.
Blood collected in tubes was centrifuged within 1 h
after sampling to obtain plasma. EDTA samples were
centrifuged after 1–2 h, with a maximum of 4 h after
sampling due to the fact that these samples were first
analyzed for hemocytometric parameters for regular pa-
tient care. This period does not affect the Phe and Tyr
concentrations in these tubes to a large extent; i.e. +
4.7% for Phe and no bias for Tyr [17]. Plasma was stored
at − 20 °C for 1–5 days prior to analyses. Plasma concen-
trations were determined using a commercial method
based on ion exchange chromatography with post col-
umn derivatization with Ninhydrin on a Biochrom 30+
or Biochrom 30 analyser (Pharmacia Biotech, Cam-
bridge, UK) (for sample preparation, we refer to van
Vliet et al. [18]). A physiological amino acid calibration
standard was used for calibration (Sigma-Aldrich, Darm-
stadt, Germany). External quality control samples (ERN-
DIM) showed excellent accuracy, precision and recovery.
The method was linear up to at least 1750 μM. Limits of
quantification (LOQ) were determined based on the
CV > 20% criterion and were 0.5 μM for Phe and 2.0 μM
for Tyr. Variation coefficients of the internal quality con-
trol samples during the study period are shown in the
Supplemental materials. DBS Phe and Tyr concentra-
tions were determined using liquid chromatography tan-
dem mass spectrometry (LC-MS/MS) analysis. For more
details on this method we refer to the Supplemental
materials.
Statistical analyses
To compare Phe and Tyr concentrations in different
sampling methods, Passing and Bablok regression ana-
lyses were performed, as recommended by the Clinical
and Laboratory Standards Institute [19]. The Passing
and Bablok regression analysis is a linear regression pro-
cedure without assumptions regarding the distribution
of samples and measurement errors, and is less sensitive
to outliers. The EP09-A3 protocol recommends analyz-
ing a minimum of 40 samples [19, 20]. The intercept
(representing constant bias) and slope (representing pro-
portional bias) are presented as estimates and should
ideally not be different from 0 (intercept) and 1 (slope),
at p < 0.05. In addition, Bland Altman tests for relative
differences were performed to visualize the relation be-
tween bias and concentration. The relative differences
are expressed as percentages of the mean concentration.
All statistical analyses were performed using IBM SPSS
Statistics 23rd version and Analyse-it for Microsoft Excel
4.18.6 (Analyse-it Software, Ltd).
Results
Table 1 shows the results of the Passing and Bablok re-
gression analyses for the comparison of the Phe and Tyr
concentrations of LH- and EDTA-anti-coagulated plasma,
and capillary DBS and their respective correlation coeffi-
cients. Only the significant and the most notable results
Table 1 Results on Passing-and-Bablok-fit analyses for phenylalanine and tyrosine concentrations in LH plasma, EDTA plasma, and
capillary DBS
Phenylalaninea Lithium heparin (LH) plasma EDTA plasma Capillary blood spot
Median (range) intercept slope R intercept slope R intercept slope R
LH plasma 326 (20–1574)
EDTA plasma 321 (23–1707) −2.1 1.10* 0.991
Capillary DBS 325.5 (26.8–1580) 2.8 1.00 0.993 9.7 0.92* 0.978
Venous DBS 309 (25.9–1490) 7.5 0.98 0.990 6.1 0.93* 0.981 0.7 1.01 0.984
LH DBS 297 (23.5–1610) 6.5 0.96* 0.996 4.7 0.88* 0.985 −0.7 0.98 0.991
EDTA DBS 311 (26.4–1550) 6.3 0.96* 0.995 5.9 0.89* 0.984 −0.6 1.00 0.992
Tyrosinea LH plasma EDTA plasma Capillary blood spot
Median (range) intercept slope R intercept slope R intercept slope R
LH plasma 61 (25–804)
EDTA plasma 72 (29–912) 0.0 1.12* 0.982
Capillary DBS 68.25 (24.2–881) 6.4* 1.02 0.930 6.8* 0.93* 0.903
Venous DBS 67 (26.8–871) 3.3 1.04 0.934 4.6 0.92* 0.934 −0.9 0.99 0.934
LH DBS 64.1 (23.1–845) 1.8 1.05 0.951 −0.1 0.96 0.937 −4.1 1.01 0.964
EDTA DBS 70.9 (24.1–793) 4.5 0.98 0.959 4.7 0.91 0.934 −1.3 0.97 0.959
aThe methods in the upper row (x) were compared to parameters in the left column (y), where y = intercept + slope * x. Results with an asterix represent
significant differences with p < 0.05 (intercept significantly different from 0; slope significantly different from 1)
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will be addressed further. In total, 6.9% of our data was
missing (15 EDTA plasma samples, 3 capillary DBS, and 4
EDTA DBS). As can be observed in Table 1, the Passing
and Bablok regression analyses of the comparison of LH
plasma and capillary DBS for Phe showed no differences.
The regression analyses for Tyr showed a higher intercept
but a normal slope. These Passing and Bablok regression
analyses of the post-correction data are also presented in
Fig. 1.
Phe and Tyr concentrations in LH plasma were higher
compared to LH DBS and EDTA DBS for Phe (4% for
both), and (slightly) higher compared to capillary DBS
Fig. 1 Results on Passing and Bablok fit analyses comparing a) phenylalanine concentrations from lithium heparin (LH) plasma and capillary dried
blood spots (DBS) and b) tyrosine concentrations from LH plasma and capillary DBS
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for Tyr (intercept: 6.4 μmol/L). No differences could be
demonstrated between LH plasma and other DBS. The
Bland Altman difference plot (Fig. 2) revealed that there
might be differences between LH plasma and capillary
DBS for Phe concentrations of approximately < 50 μmol/
L, i.e. low for PKU. In this Phe range, Phe concentra-
tions in LH plasma tended to be lower than Phe concen-
trations measured in capillary DBS. This was mainly due
to three outliers, deriving from TT1 patients with low
Phe concentrations (see Fig. 2).
No differences in Phe and Tyr concentrations were ob-
served when comparing all different DBS sampling
methods to each other (data not shown). Phe and Tyr
concentrations measured in EDTA plasma were gener-
ally 7–12% higher compared to the other sampling types,
except for LH DBS and EDTA DBS for Tyr.
Discussion
To the best of our knowledge, our study is the first to
report the potential differences between DBS and plasma
Phe and Tyr concentrations in a wide concentration
range, using data from both PKU and TT1 patients.
Moreover, we investigated the differences between Phe
and Tyr concentrations measured in different venous
plasma samples and different DBS. Our results showed
that differences, if any, are small with the applied analyt-
ical methods and DBS-plasma correction factor. To
summarize our main findings: (1) no significant differ-
ences were observed between venous DBS and capillary
collected DBS, (2) overall, LH plasma agreed well with
the other ways of blood sampling, however when Phe
concentrations are below approximately 50 μmol/L, i.e.
low for PKU patients and usual for TT1 patients, differ-
ences with capillary DBS tended to appear (with Phe
concentrations being lower in LH plasma), and (3) Phe
and Tyr concentrations tended to be higher in EDTA
plasma compared to other specimens.
Before discussing the results in more detail, some
methodological issues are addressed. TT1 is a very rare
inborn error of metabolism, also when compared to
PKU. Only few TT1 patients could be included, and
therefore our samples mostly derived from patients with
high Phe and low/normal Tyr concentrations. The DBS-
plasma correction factor therefore also mainly derived
from samples of PKU patients, i.e. with low Tyr and high
Phe concentrations. However, since both PKU and TT1
are being monitored by DBS, and using both groups
gives the possibility to compare the full range of Phe and
Tyr concentrations, we were interested in both patient
groups.
Regarding the different ways of DBS sampling, our re-
sults showed no differences between capillary DBS,
which are normally taken at home, and venous DBS,
which are spotted at our outpatient clinic to enable Phe
and Tyr measurement in DBS without needing an extra
finger puncture in our patients. These results implicate
that DBS sampled at home and at the outpatient clinic
are considered to be comparable and can be used inter-
changeably. This finding has not been reported previ-
ously, but is important, because (1) most laboratories
use DBS made of venous blood for validation purposes,
(2) in our laboratory the DBS method is calibrated/cor-
rected using DBS and plasma samples taken at the
Fig. 2 Results on Bland Altman analyses for phenylalanine concentrations measured in lithium heparin (LH) plasma compared to capillary dried
blood spots (DBS)
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outpatient clinic and (3) if a DBS needs to be taken in
the hospital alongside blood collection in tubes, it is
both more efficient and patient-friendly to make a DBS
from venous blood instead of capillary collected blood.
When comparing LH plasma to the other specimens,
several (small) differences were observed, in particular
for Phe concentrations. Interestingly, when we look at
the agreement between the different methods by Bland
Altman, a bias is especially observed in the lower Phe
range with lower Phe concentrations in LH plasma when
compared to capillary DBS. Particularly in this range, the
differences between plasma and DBS are clinically rele-
vant since low Phe concentrations have been associated
with impaired growth, skin problems, and neurological
deficits in both TT1 and PKU patients [5, 21]. For this
reason, Phe supplementation is sometimes recom-
mended in TT1 in case of persistently low Phe levels [4,
5, 7]. Furthermore, especially this lower range might be
important with the upcoming new treatment for PKU
patients, pegvaliase [22, 23]. Patients treated with pegva-
liase often have low Phe concentrations, which can drop
below the detection limit. The number of samples in this
study with low Phe concentrations is however low and it
should be noted that the observed bias may also be
caused by the three outlying values. It is therefore un-
known if this observed difference in the low Phe range is
indeed real. Furthermore, the cause of this possible
concentration-dependent difference remains unknown
and further investigations with a higher number of sam-
ples with low Phe concentrations are needed.
The methods used to analyze plasma and DBS Phe
concentrations both proved to be linear in the investi-
gated concentration range, and concentrations were well
above the limits of quantification. However, it is hypoth-
esized that analytical challenges associated with DBS
analyses could play a role causing high variability, in-
cluding influences of hematocrit variation, chromatog-
raphy effects on filter cards [24], and possibly inherent
differences in Phe concentrations in capillary and venous
blood. Factors associated with home blood sampling, in
particular applied blood volumes, affecting e.g. spot vol-
ume per punch and extraction recoveries [25], were less
likely to contribute because sampling occurred under
controlled conditions at the outpatient clinic.
A surprising finding was that Phe and Tyr concentra-
tions in EDTA plasma were 7–12% higher when com-
pared to all other samples (Table 1). These differences
have not been previously reported and so far, we have
not been able to explain this difference. Since LH and
EDTA plasmas of patients were analyzed in a single ana-
lytical run, analytical bias is not likely.
Several authors have investigated differences between
plasma and DBS Phe and Tyr concentrations [9–12], but
results are conflicting. Regarding Phe concentrations,
only the study of Allard et al., who measured Phe and
Tyr with both HPLC and flow-injection MS/MS (neo-
natal screening kit) methods, showed similar Phe con-
centrations in DBS and plasma [10]. All others reported
lower Phe concentrations in DBS [9, 11, 12]. Stroup
et al. reported significantly lower Phe concentrations in
capillary DBS with a flow-injection MS/MS method and,
to a lesser extent with ion exchange chromatography,
compared to EDTA plasma [9]. Since we also found
lower concentrations in DBS compared to EDTA
plasma, it is possible that difference reported by Stroup
et al. might, at least to some extent, be caused by the
use of EDTA plasma rather than a structural difference
between concentrations measured in plasma and in DBS.
However, other studies also showed lower Phe concen-
trations in DBS compared to LH plasma [11, 12], indi-
cating that other factors beside the used anti-coagulant
cause the observed differences. One of these may be the
difference between the analytical methods for DBS phe,
i.e. flow-injection MS/MS analyses having lower DBS
Phe concentrations compared to HPLC. This was also
demonstrated by others [9, 10, 26], and may reflect dif-
ferences in calibration and the applied extraction proce-
dures. Reports on the Tyr concentration differences
between plasma and DBS are scarce and inconclusive
like with Phe. For instance, Allard et al. [10] reported no
differences, and Groselj et al. [12] reported a 15.5%
lower concentration in DBS.
Clinicians should be aware that large differences in
DBS concentrations might exist between laboratories
and between DBS and plasma, depending on the applied
methods for calibration. Lack of standardization between
methods impairs clinical decision making, since cut-off
values for PKU and TT1 have been established to repre-
sent cut-offs for both plasma and DBS. Our results show
that laboratories can achieve similar (mean) results of
DBS and plasma, using DBS-plasma correction factors.
Laboratories should however determine their own cor-
rection factor, since this is dependent on filter card
types, and extraction and calibration protocols. Applica-
tion of such a correction factor might generate better
agreement between plasma and DBS samples, as is done
regularly when using Point-Of-Care-Testing glucose me-
ters. Standardization of the calibration procedure, i.e. ap-
plication of lab-specific DBS-plasma correction factors,
also improves the comparison of DBS and plasma Phe
and Tyr concentrations within and between laboratories,
which is essential in the development and adherence to
guidelines for the monitoring of PKU and TT1 patients.
To increase the inter-laboratory comparability, and there-
fore the applicability of both cut-off values from guide-
lines, the plasma method applied as gold standard, should
be a method that is harmonized, preferably to inter-
national calibration standards, and be tested regularly in
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external quality control schemes, such as that provide by
ERNDIM.
The large variability between DBS and plasma is more
difficult to control. It has been shown that bias between
plasma and DBS samples might be different among indi-
viduals [9]. Individually based differences may be caused
by differences in hematocrit, home blood sampling tech-
niques including applied blood volumes on the filter
card, or unknown factors such as transport of the sam-
ples [9, 27, 28]. This was not investigated in this study
since almost all patients were only included once and
samples were taken in the outpatient clinic under con-
trolled conditions. The high variability however, might
be an explanation for the outliers that were observed.
Even though measurements of metabolites in DBS
have (mainly) logistic advantages over measurements in
plasma, the confounding pre-analytical factors invalidate
the use of DBS for (home) monitoring. Regular educa-
tion of patients on the DBS sampling procedure is essen-
tial to obtain reliable results. When DBS concentrations
approach critical levels, a repeat measurement in plasma
is advisable, if possible. In theory, monitoring using a
Point-of-Care testing method for Phe and Tyr avoids the
pre-analytical errors that are associated with DBS sam-
ples, and may not only decrease the total turn-around-
time of the analyses, but may also result in lower vari-
ability and low bias, again when plasma-based calibrators
are applied.
Conclusions
In conclusion, using a DBS-plasma correction factor, our
results show comparable Phe and Tyr concentrations in
plasma and DBS. We recommend each laboratory to de-
termine such a correction factor to improve the correl-
ation between Phe and Tyr concentrations measured in
venous blood and in DBS. Especially when relating
metabolic control to clinical outcomes, it is important to
keep in mind that there are differences between various
blood sampling methods and that these might especially
be dependent on the calibration method that is used.
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